Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
| Autor: | Hong-Wei Wu, Jemily Malvar, Wesley E. Barry, Grace E. Asuelime, Michael A. Sheard, Jeremy R. Jackson, Zesheng Wan, Larry Wang, Eugene S. Kim, Jianping Sun, Robert C. Seeger |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cytotoxicity
Immunologic 0301 basic medicine Cancer Research medicine.medical_treatment Article Mice Neuroblastoma 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Animals Humans Medicine Bioluminescence imaging biology business.industry Antibodies Monoclonal Dinutuximab Immunotherapy medicine.disease Combined Modality Therapy Primary tumor Antibodies Anti-Idiotypic Killer Cells Natural Disease Models Animal 030104 developmental biology medicine.anatomical_structure Oncology Cell culture 030220 oncology & carcinogenesis biology.protein Cancer research Heterografts N-Acetylgalactosaminyltransferases Bone marrow Antibody business |
| Zdroj: | Clinical Cancer Research. 25:325-333 |
| ISSN: | 1557-3265 1078-0432 |
| Popis: | Purpose: Immunotherapy of neuroblastoma that remains after myeloablative chemotherapy with anti-GD2 antibody dinutuximab has increased the two-year event-free and overall survival of high-risk neuroblastoma patients; however, 40% of patients develop recurrent disease during or after this treatment. To determine the potential of such antibody-based immunotherapy earlier in treatment, a mouse model was developed in which surgical resection of the primary tumor was followed by therapy of residual disease with dinutuximab combined with ex vivo–activated human natural killer (aNK) cells. Experimental Design: The effect of combining dinutuximab with human aNK cells was determined in vitro with cellular cytotoxicity and Matrigel invasion assays. The in vivo efficacy of dinutuximab and aNK cells against neuroblastoma was assessed following resection of primary tumors formed by two cell lines or a patient-derived xenograft (PDX) in immunodeficient NOD-scid gamma mice. Results: In vitro, the combination of aNK cells and dinutuximab caused cytotoxicity and decreased invasiveness of three human neuroblastoma cell lines. Treatment of mice with dinutuximab combined with aNK cells after surgical resection of primary intrarenal tumors formed by two cell lines or a PDX decreased tumor cells in liver and bone marrow as evaluated by histopathology and bioluminescence imaging. Survival of mice after resection of these tumors was most significantly increased by treatment with dinutuximab combined with aNK cells compared with that of untreated mice. Conclusions: The combination of dinutuximab and adoptively transferred human aNK cells following surgical resection of primary neuroblastomas significantly improves survival of immunodeficient mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|